Enovis Corporation
ENOVEnovis Corporation (ENOV) is a global medical device company specializing in orthopedics, regenerative medicine, and surgical solutions. It provides innovative products designed to improve patient outcomes and enhance healthcare. The company focuses on delivering surgical instruments, implants, and regenerative therapies across various medical specialties.
Company News
Enovis Corporation (NYSE: ENOV) announced it will host an investor conference call on August 6th, 2026 at 8:30 a.m. Eastern Time to discuss its second quarter 2026 financial results. The company will issue an earnings press release that morning, with the live webcast and presentation accessible from its website.
The article highlights four undervalued growth stocks positioned to benefit from long-term secular trends: Enovis (orthopedic implants driven by aging population), Insteel Industries (infrastructure and data center construction), Mueller Water Products (water infrastructure replacement), and Proto Labs (transitioning from prototyping to productio...
Front Street Capital Management purchased 384,124 additional shares of Enovis (ENOV) in Q1 2026 for approximately $9.08 million, increasing their stake to 2.25% of fund assets. The purchase signals institutional confidence in the medical device company despite ENOV shares being down 23.99% over the past year. Insider buying activity also suggests...
Enovis Corporation (NYSE: ENOV) announced it will host an investor conference call on May 7th, 2026 at 8:30 a.m. ET to discuss first quarter 2026 financial results. The company reported continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically, with Reconstructive sales growing 10% year-over-year ...
John Kleckner, Principal Accounting Officer of Enovis Corporation, purchased 2,468 shares on Nov. 25, 2025, signaling potential confidence in the company despite a challenging year with significant quarterly losses.
